GlaxoSmithKline Sample Clauses

GlaxoSmithKline. In view of the impact that the GC’s judgment in GSK had on the general perception of restrictions by object, it warrants careful consideration.178 The judgment triggered an intense, though overdue, academic debate on the legal interpretation of the object criterion and also encapsulated the GC’s more ambitious assertions. Here the GC reversed the Commission’s decision that GlaxoSmithKline’s general sales conditions restricted competition by reason of their object, though it upheld the finding that the agreement was a restriction of competition by effect. The case concerned the general sales conditions of GlaxoSmithKline in respect of its wholesalers in Spain. In particular, clause 4 (which was contained within the general sales conditions) provided for a dual pricing system. This meant that there was a distinction between prices charged to Spanish wholesalers in the case of 175 Supra n170, Volkswagen, para 230. 176 Ibid, para 230. The GC then cites ENS, paras 93 to 95 and 105 in support. The GC does not refer to para 136 of ENS, which directly contradicts this. Alternatively, the GC may not have intended any real significance to be placed on its use of wording: arguably all it meant was that no actual effects need be taken into account when the object of an agreement is to restrict competition. 177 Supra n170, Volkswagen, para 178. By using the word “proved” the GC raised the bar in terms of the standard of proof required to determine the object of an agreement. This also implies it is imperative that the object element is fully discharged before turning to the effects of an agreement. 178 Supra n73 GSK. domestic resale and higher prices charged in the case of exports to any other Member State.179 The GC examined in detail whether clause 4 of the general sales conditions was a restriction of competition.180 To give a context to its findings, the GC made some bold assertions. It held that the competition referred to in Article 101 TFEU “is taken to mean effective competition, that is to say, the degree of competition necessary to ensure the attainment of the objectives of the Treaty”.181 It reaffirmed that price competition is not the only effective form of competition or that to which all absolute priority must be given.182 As such: “...a restriction of competition within the meaning of Article 101 must take account of the actual framework and, therefore, of the legal and economic context in which the agreement to which that restriction is imputed is deplo...
Sample 1
AutoNDA by SimpleDocs
GlaxoSmithKline. First pre-pandemic vaccine approved to help protect against pandemic influenza. 2008 [updated May 19, 2008; cited 2011]; Available from: xxxx://xxx.xxx.xxx/media/pressreleases/2008/2008_pressrelease_10048.htm.
Sample 1
GlaxoSmithKline. In December 2000, Gilead entered into an agreement with Glaxo Wellcome, now GlaxoSmithKline ("Glaxo") giving Gilead the rights to GS 7904L, a novel anti-tumor compound. Gilead is developing GS 7904L in a liposome and is evaluating it in preclinical studies. Under this agreement, Gilead has exclusive worldwide rights to develop and commercialize GS 7904L for all indications other than malaria. Gilead paid Glaxo an upfront fee which was included in R&D expense in 2000, and may be required to make additional payments to Glaxo if certain developmental goals related to regulatory approval are achieved. Additionally, if the product is successfully commercialized, Gilead would be required to pay Glaxo a percentage of the product's net sales. The agreement expires ten years after the first commercial sale of the product or the date the last related patent expires. In May 1998, Gilead entered into a three-part collaboration with Glaxo in which (a) Glaxo received a non-exclusive right to use Gilead's proprietary SELEX process for target validation; (b) Gilead received the exclusive rights (subject to Glaxo's right to elect to participate in such activities) to develop and commercialize NX 211, a liposomal formulation of Glaxo's proprietary topoisomerase I inhibitor (lurtotecan); and (c) Glaxo acquired 728,514 shares of Gilead common stock for $10.0 million in a private offering. In December 2000, the collaboration and license agreement was 79 GILEAD SCIENCES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED) DECEMBER 31, 2000
Sample 1
GlaxoSmithKline. We are a science-led global healthcare company, making a range of products that treat major disease areas including – asthma, virus control, infections, mental health, diabetes, cardiovascular and digestive conditions that help people do more, feel better and live longer. In Vietnam, our mission is to bring more medicines/ vaccines of value to more Vietnamese patients and making these accessible to as many people who need them. We aim to reach nearly 5 million patients by 2020 though continuing to drive our efforts to build a patient-focused sustainable organization. Belief in the GSK Values underpins everything we do in Vietnam! Jhpiego Jhpiego is an international, non-profit health organization affiliated with Xxxxx Xxxxxxx University. For 40 years and in over 155 countries, Jhpiego has worked to prevent the needless deaths of women and their families. Jhpiego works with health experts, governments and community leaders to provide high-quality health care for their people and to strengthen health systems. Jhpiego has previously worked in Vietnam to improve the quality of preservice (undergraduate) medical education programs in maternal, reproductive and neonatal health in the Hue Medical Faculty. Jhpiego would welcome additional opportunities to partner with stakeholders in Vietnam to advance the availability of high quality health care services to women and their families. Xxxxxxx & Xxxxxxx Caring for the world, one person at a time… inspires and unites the people of Xxxxxxx & Xxxxxxx. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Employees of Xxxxxxx & Xxxxxxx Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. We have 265 operating companies in more than 60 countries employing approximately 126,500 people. In Vietnam, Xxxxxxx & Xxxxxxx has been providing a wide range of healthcare products, medical devices and diagnostics under Xxxxxxx & Xxxxxxx Vietnam Co. Ltd and Xxxxxxx – Cilag Ltd. Representative Office to address the unmet needs of doctors, patients and consumers all over the country for more than 20 years. Xxxx Xxxxxxx Nutrition Xxxx Xxxxxxx Nutrition is a world leader in infant and children’s nutrition, dedicated to nourish the world’s children for the best start in life. For more than a century, Xxxx Xxxxxxx is committed to advancing the science of pediatric nutrition around the wor...
Sample 1
GlaxoSmithKline. 1. Lease Agreement Dated November 25th, 2009 by and between VIF II/YORK, LP., a Delaware limited partnership and GLAXOSMITHKLINE CONSUMER HEALTHCARE, LP, a Delaware limited partnership.
Sample 1

Related to GlaxoSmithKline

  • Baxter and Nexell shall cooperate in any action taken by a third party solely involving a nullity action, opposition, reexamination or any other action taken by such third party alleging the invalidity or unenforceability of any Licensed Intellectual Property. Both parties agree to share equally in the cost of the defense of such Licensed Intellectual Property.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Cornerstone shall notify the LLC and confirm such advice in writing (i) when the filing of any post-effective amendment to the Registration Statement or supplement to the Prospectus is required, when the same is filed and, in the case of the Registration Statement and any post-effective amendment, when the same becomes effective, (ii) of any request by the Securities and Exchange Commission for any amendment of or supplement to the Registration Statement or the Prospectus or for additional information and (iii) of the entry of any stop order suspending the effectiveness of the Registration Statement or the initiation or threatening of any proceedings for that purpose, and, if such stop order shall be entered, Cornerstone shall use its best efforts promptly to obtain the lifting thereof.

  • Business Development Company Buyer is a business development company as defined in Section 202(a)(22) of the Investment Advisors Act of 1940.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Technology Transfer Subject to the terms of the Development Supply Agreement, as soon as reasonably practicable, but in no event later than the fifth (5th) anniversary of the Effective Date, Alnylam shall initiate a technology transfer to MedCo, or to its Third Party manufacturer(s) of Licensed Product, selected by MedCo and reasonably acceptable to Alnylam, of Alnylam Know-How that is reasonably necessary or useful for the Manufacture of the Licensed Product, and shall make available its personnel on a reasonable basis to consult with MedCo or such Third Party manufacturer(s) with respect thereto, all at MedCo’s expense, including the Costs reasonably incurred by Alnylam in connection with such technology transfer activities. MedCo shall reimburse Alnylam such Costs incurred with respect to such Manufacturing technology transfer within [***] days after receipt of an invoice therefor. Alnylam and its Affiliates shall keep complete and accurate records in sufficient detail to enable the payments payable hereunder to be determined. Alnylam shall not be required to perform technology transfer to more than one Third Party manufacturer for each stage of the Licensed Product supply chain (i.e., Bulk Drug Substance, Bulk Drug Product and Finished Product). Promptly after MedCo’s written request, Alnylam shall use Commercially Reasonable Efforts to assign to MedCo any manufacturing agreement between Alnylam and a Third Party that is solely related to the manufacture of Licensed Products. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party and MedCo’s written agreement to assume all the obligations of Alnylam under such agreement to be undertaken after such assignment, but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, MedCo shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacture to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such agreement between MedCo and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to MedCo.

  • Research Funding Genocea shall pay to Isconova in total [* * *] payable as follows: (i) $[* * *] in equal monthly installments for each remaining month in 2009 following the Effective Date and (ii) $[* * *] in equal monthly installments during the period from January 1, 2010 until March 31, 2012. The Research Funding shall be used solely for the performance of activities under the Research and Phase 1 Supply Plan and the Development and Scale-Up Plan and, for the avoidance of doubt, solely to fund Development and research activities for human (and not veterinary) applications in accordance with such Research and Phase 1 Supply Plan and Development and Scale-Up Plan. Notwithstanding anything to the contrary above, the Parties agree that this restriction shall only apply to the allocation and use of the Research Funding as such, and shall not be construed as limiting or affecting the ownership of any Isconova Technology and Joint Technology created, conceived, reduced to practice or Invented hereunder. Isconova’s ownership and/or rights to the Isconova Technology and Joint Technology shall exclusively be governed by the provisions in Section 3.3. and Isconova’s use of the Isconova Technology and Joint Technology shall be subject only to the licenses granted to Genocea in Sections 3.1.1 through 3.1.3. Isconova shall during the Research Term allocate not less than two (2) dedicated FTEs for Isconova’s research work for Genocea hereunder and each such dedicated FTE shall be paid through Research Funding. During the Research Term, Isconova shall, within fifteen (15) days after the end of each month, deliver to Genocea a report setting forth the number of Isconova FTEs that worked on activities under the Development and Scale-Up Plan and the Research and Phase 1 Supply Plan, as well as other costs and expenses of Isconova evidencing recourses spent on Isconova’s research work hereunder. Researching Funding THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. payments shall be made within fifteen (15) days after the end of each calendar month.

  • Innovations As used in this Agreement, the term “Innovations” means all processes, machines, manufactures, compositions of matter, improvements, inventions (whether or not protectable under patent laws), works of authorship, information fixed in any tangible medium of expression (whether or not protectable under copyright laws), moral rights, mask works, trademarks, trade names, trade dress, trade secrets, know-how, ideas (whether or not protectable under trade secret laws), and all other subject matter protectable under patent, copyright, moral right, mask work, trademark, trade secret or other laws, and includes without limitation all new or useful art, combinations, discoveries, formulae, manufacturing techniques, technical developments, discoveries, artwork, software, and designs. “Innovations” includes “Inventions,” which is defined to mean any inventions protected under patent laws.

Time is Money Join Law Insider Premium to draft better contracts faster.